Project Grant HT94252310830
Award Date
8/15/23
Completion Date
8/14/25
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
The Trustees of Columbia University in the City of New York (Columbia University) was awarded a $658,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2026 targeting inflammatory signals as therapeutic strategies for peripheral T-cell lymphoma. Through this award, Columbia University will investigate medical solutions for lymphoma, a type of cancer...
The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, was awarded a $656,272 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research aimed at optimizing PD-1 immunotherapy through increased T cell regeneration and reduced antigen load. This 2-year project will be conducted in New York, NY from September 1, 2023 to August 31, 2025. The Military Medical...
The Defense Health Agency awarded a $610,656 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The grant, effective March 1, 2025 through February 29, 2028, is for research to decipher epigenetic mechanisms that dictate poor responses to KRAS inhibition in lung cancer. As a prominent academic research institution, Columbia University will...
The Department of Defense's Defense Health Agency awarded a $1,330,054 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of California, San Francisco (UCSF). The grant supports the "CLINICAL VALIDATION AND IMPLEMENTATION OF A HOST-PATHOGEN-BASED DIAGNOSTIC ASSAY FOR EARLY LYME DISEASE AND OTHER TICK-BORNE INFECTIONS" project, with a performance period from July 1, 2024 to June 30, 2027. As a leading academic medical...
The Defense Health Agency awarded a $456,633 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. The grant funds the development and optimization of a platform for next-generation monoclonal antibodies against Powassan virus and other neuroinvasive tick-borne viruses. Key collaborators include researchers from the United States Army Medical Research Institute of Infectious...
This $1,644,999.00 Project Grant award was made by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The grant funds research on "The Role of Streptococcus in Esophageal Neoplasia" over the period from July 1, 2025 to June 30, 2028. As a prominent academic research institution, Columbia University will leverage...
The Trustees of Columbia University in New York City will receive $567,000 from the Department of the Army Medical Command under a three-year Project Grant award to identify epigenetic vulnerabilities in peripheral T-cell lymphomas. The grant period runs from September 1, 2022 through August 31, 2025. The funding supports research conducted under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health through innovative biomedical...
This federal Project Grant award of $1,645,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at The Trustees of Columbia University in the City of New York to treat HER2 therapy-resistant brain metastasis using antidepressants. The award, with a period of performance from July 1, 2025 to June 30, 2028, will fund innovative biomedical research at the university's Health Sciences Division to investigate...
The Defense Health Agency awarded Duke University a $1,255,621 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop diagnostic and therapeutic agents targeting Borrelia burgdorferi, the causative agent of Lyme disease. The grant, with a performance period from September 15, 2024 to September 14, 2027, will enable Duke to conduct innovative biomedical research aimed at improving health outcomes for military service members and the broader public. As a...
The Defense Health Agency awarded a $1,695,794 Project Grant to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to develop a state-of-the-art microbur-driven non-absorbable epithelial SERT antagonist to treat anxiety and depression in military members and the general public. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program, which supports basic, applied, and advanced biomedical research to...